Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with recurrent
diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.